Róbert Wessman
Tracked across 4 events · 26 articles · First seen Apr 30, 2026 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Róbert Wessman, Founder and Executive Chairman of Alvogen, will be participating in the investor conferences, representing the company's leadership and strategic vision. His presence is crucial for conveying confidence and direction to investors.
Jun 02, 2026 · 6 articles
Business
Impact: Róbert Wessman, founder and chairman of Alvogen, expressed confidence in the financing's ability to provide flexibility and support the company's growth.
Jul 01, 2026 · 7 articles
Regulatory
Impact: Founder of Alvogen; mentioned in background but not directly involved in this event.
Jul 29, 2026 · 7 articles
Business
On August 21, 2026, Alvogen announced a strategic licensing and commercialization agreement with Rhythm Pharmaceuticals covering two biosimilar candidates: AVT34 (proposed biosimilar to Imfinzi/durvalumab) and AVT87 (proposed biosimilar to Hemlibra/emicizumab). Under the semi-exclusive U.S. agreement,…
Impact: Róbert Wessman is the founder of Alvogen, but he is not directly involved in this agreement.
Aug 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Róbert Wessman live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard